The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monday Biotech Deal Review: September 28, 2009

B&W_BigNickelLots of deal news this week, including the Canadian action noted at the time: the iCo-CPDD deal and ethica’s in-license transaction.  Plus there was plenty of international excitement today (repentance notwithstanding) with Abbott’s $6.6 billion Solvay play and J&J’s new 18% stake in Crucell.  Keep reading for a securities-palooza and plenty more

Securities-palooza:

Take-Over Do-Overs

In Debt to Investissement Québec

Aegera Therapeutics, which fully drew down a $7 million debt facility provided by Investissement Québec in order to fund its oncology and diabetic neuropathic pain programs, currently has its lead product at Phase 2b for an AML indication.

An Academic Collaboration in Flux:

Primera Bioscience Research Inc. is at a turning point in its collaboration with The Hospital for Sick Children.  Primera has funded $200,000 of the $300,000 project and has postponed the final payment pending agreement on the research strategy.  In the meantime, Primera sold 375,000 common shares at $0.10 per share to arm’s length subscribers — the same price for which common shares were sold under Primera’s 2008 prospectus. The $37,500 gross proceeds will apparently fund Primera’s general and administrative expenses for the next three years.

Bookmark and Share

About these ads

One response to “Monday Biotech Deal Review: September 28, 2009

  1. Pingback: Monday Biotech Deal Review: August 9, 2010 | The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 131 other followers